As the VDGs directly reflected vascular-specific anti-VEGF downstream effects in various experimental models and clinical dataset, an exquisite delineation of its relation to molecular subtypes and disease prognosis in ovarian cancer may advance our understanding of the VEGF pathway and provide a promising diagnostic strategy for identifying a patient subpopulation likely to derive benefit from anti-VEGF treatment. This evidence concerns the gene VEGFA and ovarian carcinoma.